Bayer Healthcare LLC

Mark Lynch

Olaf Weber

Uday R Khire

Davoud Asgari

Chunguang Wang

Jianxing Shao

Barry Hart

Xiao-Gao Liu

Dhanapalan Nagarathnam

Jacques P Dumas

William Johnston Scott

Gaetan H Ladouceur

Stephen Boyer

Scott Wilhelm

Lei Wang

Lei Zhang

Donald Bankston

Dhanaphalan Nagarathnam

The present invention provides methods for treating and/or preventing conditions and diseases in humans and other mammals that are associated with and/or mediated by signal transduction pathways comprising platelet-derived growth factor receptor (PDGFR) by administering diaryl ureas of Formula I. The present invention also provides devices and methods for treating, ameliorating, preventing, or modulating restenosis following angioplastic surgery or other invasive procedures that affect or injure the vascular system, and graft rejection following transplantation of a donor tissue into a host, where a stent or other omplantable device comprises an effective amount of diaryl ureas of Formula I.

Diaryl ureas for diseases mediated by PDGFR

Disclosed are compounds and derivatives thereof their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.

Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors

A process for the preparation of various quinazoline compounds which are useful as Rho-Kinase inhibitors, and thus having utility in the treatment of hypertension and other indications.

Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof

Growing community of inventors

Madison, CT, United States of America

Mark Lynch